National Conference on Alternatives to Animal Experiments New Delhi | November 2018

Toward a Human-Focused Paradigm in Health Research

THE BEDMED VISION


Troy Seidle

Vice President Research & Toxicology

tseidle@hsi.org

BioMed21.org





- HSI is active on the ground in 60 countries, including India and Asia-Pacific, Europe and the Americas
- Our Research & Toxicology Department brings together experts in biomedicine, eco/toxicology & regulatory science, public policy, etc.
- Working with research institutes, companies, government regulators, policy-makers and other stakeholders
- OECD expert groups, national government advisory bodies on alternative methods and product safety, etc.


Advancing humanpredictive approaches in regulatory testing & health

research

worldwide

Age-old dilemma in health research & drug discovery





Animal models

Systemic but not human(e)


Static 2D & 3D human cell models

Human but not systemic





High failure rates for drug candidates that appear safe and effective preclinically



"Most of this failure is due to the **limited predictive value** of preclinical models."

Plenge et al. Nat Rev Drug Discov. 2013; 12: 581-94; Kola & Landis. Nat Rev Drug Discov. 2004; 3; 711-15






"We have moved away from studying human disease in humans... The problem is that **it hasn't worked**, and it's time we stopped dancing around the problem... We need to refocus and **adopt new methodologies** for use in humans, **to understand disease biology in humans**."









Tox21 vision

Transform toxicity testing from a system based on whole animal testing to one founded primarily on *in vitro* methods that evaluate changes in biologic processes using cells, cell lines, or cellular components, preferably of human origin."


TOXICITY TESTING IN THE 21ST CENTURY A VISION AND A STRATEGY








Adverse outcome pathways (AOPs) as an organizing framework







Tox21 vision >> animal-free human risk assessment





Adapted from Dr AH Piersma – Evolution vs Revolution in Innovating Regulatory Toxicity Testing" – June 2018, RIVM, Utrecht



Articulating a **scientific vision** of '21st century' biomedical research



* The views expressed in this article are those of the authors and do not necessarily reflect the views or policies of their organizations.

BioMed21 scientific vision >> human biology as the 'gold standard'



ehponline.org

Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research

http://dx.doi.org/10.1289/ehp.1510345

SUMMARY: Biomedical developments in the 21st century provide an unprecedented opportunity to gain a dynamic systems-level and human-specific understanding of the causes and pathophysiologies of disease. This understanding is a vital need, in view of continuing failures in health research, drug discovery, and clinical translation. The full potential of advanced approaches may not be achieved within a 20th-century conceptual framework dominated by animal models. Novel technologies are being integrated into environmental health research and are also applicable to disease research, but these advances need a new medical research and drug discovery paradigm to gain maximal benefits. We suggest a new conceptual framework that repurposes the 21st-century transition underway in toxicology. Human disease should be conceived as resulting from integrated extrinsic and intrinsic causes, with research focused on modern human-specific models to understand disease pathways at multiple biological levels that are analogous to adverse outcome pathways in toxicology. Systems biology tools should be used to integrate and interpret data about disease causation and pathophysiology. Such an approach promises progress in overcoming the current roadblocks to understanding human disease and successful drug discovery and translation. A discourse should begin now to identify and consider the many challenges and questions that need to be solved.


"We suggest a new conceptual framework ... with research focused on human-specific models to understand disease pathways at multiple biological levels that are analogous to adverse outcome pathways [AOPs]."

Gill Langley,1 Christopher P. Austin,2 Anil K. Balapure,3 Linda S. Birnbaum,4 John R. Bucher,5 Julia Fentem,6 Suzanne C. Fitzpatrick,7 John R. Fowle III,8 Robert J. Kavlock,9 Hiroaki Kitano,10 Brett A. Lidbury,11 Alysson R. Muotri,12 Shuang-Qing Peng,13 Dmitry Sakharov,14 Troy Seidle,15 Thales Trez,16 Alexander Tonevitsky,17 Anja van de Stolpe,18 Maurice Whelan,19 and Catherine Willett20

1 Humane Society International; 2 National Center for Advancing Translational Sciences, National Institutes of Health (NIH); 3 CSIR–Central Drug Research Institute; 4 National Institute of Environmental Health Sciences (NIEHS) and National Toxicology Program (NTP), NIH; 5 Division of NTP, NIEHS, NIH; 6 Unilever R&D, Safety and Environmental Assurance Centre (SEAC); 7 Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration; 8 Science to Inform LLC; 9 U.S. Environmental Protection Agency; 10 Systems Biology Institute; 11 Australian National University; 12 University of California, San Diego; 13 Academy of Military Medical Sciences, Beijing, China; 14 Scientific Research Centre Bioclinicum; 15 Humane Society International; 6 Federal University of Alfenas; 17National Center of Medical Radiological Research; 18 Philips Research; 19 Institute for Health and Consumer Protection, European Commission Joint Research Centre; 20 Humane Society of the United States.

* The views expressed in this article are those of the authors and do not necessarily reflect the views or policies of their organizations.

BioMed21 scientific vision >> bridging the disciplinary silos



BioMed21 Collaboration >> critical reviews & consensus-building





Liver Disease (Noor, 2015

Autism Spectrum Disorders (Muotri, 2015



Funded reviews have identified poorly predictive models & suggested novel roadmaps

- Alzheimer's disease
- Amyotrophic lateral sclerosis
- Asthma
- Autism spectrum disorder
- Autoimmune disorders
- Cardiovascular disease
- Diabetes type II
- Flaviviruses (Zika)
- Liver disease (cholestatic + NASH)
- Parkinson's disease
- Tuberculosis

... others in development



International workshop series

- Europe (Brussels, Dec. 2015)
 - Langley et al. Drug Discov. Today 2017
- Latin America (Brazil, May 2017)
 - Triunfol et al. Drug Discov. Today 2018
- North America (Bethesda, June 2017)
 - Participation from 6 NIH institutes, 5 FDA centers, co-sponsored by NIEHS
 - Marshall et al. Drug Discov. Today 2018





IMI projects contribute to the 3Rs

Eliminating poorly predictive models	Developing new improved models	Replacing animals with better <i>in vitro</i> & <i>in silico models</i>	Alternative tools
 Parkinson's Disease Diabetes Asthma Chronic Pain Schizophrenia Depression Autism 	 Parkinson's Disease Diabetes Asthma Chronic Pain Schizophrenia Depression Autism 	 Diabetes Cancer Schizophrenia Chronic pain Drug safety Parkinson's Disease 	 Biomarkers Novel cell lines 2D and 3D cell cultures Imaging Computation Simulation Pooling & novel analysis of existing data

Research and Innovation

Take-away thoughts

- Human biology as the gold standard in health research (& prioritize funding based on proof of relevance)
- » Modern, science-based terminology (e.g. human iPSCderived cancer models) vs. '3R / alternatives' bioethics lingo from 1959, which can be marginalizing
- » Visit BioMed21.org/subscribe

for news on funding opportunities, events, publications and more ONLY RELEVANT 'ANIMAL MODEL'

"Let's think outside the cage

